Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 8Plasma cell 6Lymphoid 2Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 11Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Kidney Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Wilms Tumor 1Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Melanoma 1Hematologic Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pertuzumab 3trametinib 2palbociclib 2dabrafenib 2copanlisib 2Trastuzumab 2Sunitinib 2Specimen Handling 2Sorafenib 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Immunoglobulin G 2HhAntag691 2Fluorouracil 2Disulfides 2Dasatinib 2Bevacizumab 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2venetoclax 1ulixertinib 1trastuzumab biosimilar HLX02 1temsirolimus 1sapanisertib 1ruxolitinib 1romidepsin 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Lenalidomide × Genitourinary × Clear all
NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

M.D. Anderson Cancer Center

Phase 1 Completed
180 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡